Eli Lilly's global CEO David Ricks is spearheading the worldwide launch of popular diabetes and anti-obesity drugs Mounjaro and Zepbound ... have built systems where people can seek treatment and even ...

The deal includes $11 billion upfront to buy the fill-finish sites ... notably Eli Lilly, which has also faced supply issues with diabetes therapy Mounjaro and obesity drug Zepbound, based on ...

and points out that Catalent also contracts fill-and-finish services to Eli Lilly, currently its main rival in the GLP-1 market with tirzepatide-based therapies Mounjaro and Zepbound. The two ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Now, Eli Lilly, the largest pharmaceutical company in the world in terms of market capitalisation, has launched its own version of the magic drug. Tirzepatide, or Mounjaro, as the company is ...

In short, the reason is that Eli Lilly launched Mounjaro and Zepbound three years ago [2022 and 2023, respectively], and both of these medications have competitive advantages over Novo Nordisk's ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's what you need to know. Amy Schumer has praised weight loss drug ...

Eli Lilly may look at manufacturing its weight-loss drug Mounjaro in India in future as it expands its global footprint, CEO David Ricks, who is visiting the country, has said. His comments come ...

the approval of Omvoh for Crohn's disease in March 2025 exemplifies Eli Lilly's successful product diversification strategy. The ongoing international expansion plans, particularly for Mounjaro ...

Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company. Over the last couple of years, the pharmaceutical sector has captivated investors thanks in ...